Presidio Pharma Raises $26 Million

Presidio Pharmaceuticals Inc., a San Francisco-based drug company focused on small-molecule compounds to treat HIV-1, HCV and other chronic viral infections, has raised $26 million in Series B funding. Panorama Capital led the deal, and was joined by Baker Brothers Investments, Bay City Capital, Ventures West Capital and Nexus Medical Partners. Returning Series A backers included Sagamore Bioventures, George Rathmann Fund and Peninsula Overview Partners.